TEVA PHARMS Company Profile

✉ Email this page to a colleague

TEVA PHARMS has three hundred and twenty-one approved drugs.

There are three US patents protecting TEVA PHARMS drugs. There are forty-four tentative approvals on TEVA PHARMS drugs.

There are nineteen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and forty-five supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	CHLORPROMAZINE HYDROCHLORIDE	chlorpromazine hydrochloride	TABLET;ORAL	215659-002	Oct 25, 2021	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Teva Pharms Usa	AMLODIPINE BESYLATE AND VALSARTAN	amlodipine besylate; valsartan	TABLET;ORAL	091235-002	Mar 30, 2015		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Teva Pharms Usa	ATOMOXETINE HYDROCHLORIDE	atomoxetine hydrochloride	CAPSULE;ORAL	079022-002	May 30, 2017	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Teva Pharms Usa	DOFETILIDE	dofetilide	CAPSULE;ORAL	210018-001	Apr 15, 2022		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	9,375,410	⤷ Sign Up
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	7,199,098	⤷ Sign Up
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	7,199,098	⤷ Sign Up
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,054,430	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	for Injection	3.5 mg/vial	➤ Subscribe	2016-10-26
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-01-29
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14
➤ Subscribe	Extended-release Capsule	15 mg and 30 mg	➤ Subscribe	2008-08-11
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	Injection	40 mg/mL, 1 mL pre-filled syringe	➤ Subscribe	2014-02-26
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01

Patent Number	Expiration Date
⤷ Sign Up	⤷ Sign Up

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1255752	CA 2008 00015	Denmark	⤷ Sign Up	PRODUCT NAME: SUNITINIB EVT. I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER L-MALEATSALTET
2101777	300813	Netherlands	⤷ Sign Up	PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
1304992	PA2013025	Lithuania	⤷ Sign Up	PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1613288	C300497	Netherlands	⤷ Sign Up	PRODUCT NAME: FINGOLIMOD ALSMEDE FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN, IN HET BIJZONDER FINGOLIMOD HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.